Literature DB >> 27977329

Reducing Artifacts during Arterial Phase of Gadoxetate Disodium-enhanced MR Imaging: Dilution Method versus Reduced Injection Rate.

Young Kon Kim1, Wei-Chan Lin1, Kyunghyun Sung1, Steven S Raman1, Daniel Margolis1, Yaeji Lim1, Seonhye Gu1, David Lu1.   

Abstract

Purpose To compare two contrast material-administration protocols (dilution vs slow injection) in terms of their effectiveness in arterial phase artifact reduction at gadoxetic acid-enhanced magnetic resonance (MR) imaging. Materials and Methods This HIPAA-compliant retrospective case-controlled cohort study was approved by the institutional review board, with a waiver of informed patient consent. A total of 318 consecutive patients undergoing gadoxetic acid-enhanced MR imaging were placed into one of two subcohorts of 159 consecutive patients each: the dilution subcohort (gadoxetic acid was diluted 1:1 with saline and injected at a rate of 2.0 mL/sec) and the slow injection subcohort (gadoxetic acid was not diluted and was injected at a rate of 1.0 mL/sec). Eighty-nine patients in the dilution subcohort also underwent follow-up MR imaging with the slow injection method, and 34 patients in the slow injection subcohort underwent follow-up MR imaging with the dilution method. Both patient- and image-based analyses, as well as intraindividual analysis, were used to compare two parameters-mean artifact score rated by two observers using a five-point scale and frequency of severe artifact-between the dilution and slow injection subcohorts with the Wilcoxon Mann-Whitney test, χ2 test, and generalized estimating equation. Results In both patient- and image-based analyses, the mean artifact score and frequency of severe artifact were lower in the dilution subcohort (mean, 1.46% and 3.8% [six of 159]) than in the slow injection subcohort (mean, 1.95% and 15.1% [24 of 159]) (P ≤ .001 and P < .001, respectively). In intraindividual analysis, both variables were also decreased in the dilution subcohort (P = .007 and P = .001, respectively). We found the two variables to be significantly increased in the slow injection subcohort when compared with that in the dilution subcohort for three different MR platforms (P < .05). Conclusion In comparison with slow injection of undiluted contrast material at a rate of 1.0 mL/sec, gadoxetic acid diluted to 50% and injected at a rate of 2 mL/sec had a significantly less severe ghosting artifact in the arterial phase of gadoxetic acid-enhanced MR imaging. © RSNA, 2016 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27977329     DOI: 10.1148/radiol.2016160241

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid.

Authors:  Jordi Rimola; Anna Darnell; Ernest Belmonte; Victor Sapena; Carla Caparroz; Neus Llarch; Maria Reig; Alejandro Forner; Jordi Bruix; Carmen Ayuso
Journal:  Eur Radiol       Date:  2020-06-30       Impact factor: 5.315

2.  Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.

Authors:  Yang Shin Park; Jongmee Lee; Jeong Woo Kim; Cheol Min Park; Chang Hee Lee
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

3.  Validation of Zero TE-MRA in the Characterization of Cerebrovascular Diseases: A Feasibility Study.

Authors:  S Shang; J Ye; W Dou; X Luo; J Qu; Q Zhu; H Zhang; J Wu
Journal:  AJNR Am J Neuroradiol       Date:  2019-09       Impact factor: 3.825

4.  Characterization of the arterial enhancement pattern of focal liver lesions by multiple arterial phase magnetic resonance imaging: comparison between hepatocellular carcinoma and focal nodular hyperplasia.

Authors:  Marco Gatti; Marco Calandri; Laura Bergamasco; Fatemeh Darvizeh; Luigi Grazioli; Riccardo Inchingolo; Davide Ippolito; Stefano Rousset; Andrea Veltri; Paolo Fonio; Riccardo Faletti
Journal:  Radiol Med       Date:  2020-01-08       Impact factor: 3.469

5.  Abbreviated Gadoxetic Acid-enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation.

Authors:  Jeong Woo Kim; Chang Hee Lee; Yang Shin Park; Jongmee Lee; Kyeong Ah Kim
Journal:  Radiol Imaging Cancer       Date:  2019-09-27

6.  Artifacts during the arterial phase of gadoxetate disodium-enhanced MRI: Multiple arterial phases using view-sharing from two different vendors versus single arterial phase imaging.

Authors:  Ji Hye Min; Young Kon Kim; Tae Wook Kang; Woo Kyoung Jeong; Won Jae Lee; Soohyun Ahn; Na Young Hwang
Journal:  Eur Radiol       Date:  2018-02-15       Impact factor: 5.315

7.  Predictive factors of truncation artifacts in the arterial phase of Gd-EOB-DTPA-enhanced MRI: a nationwide multicenter study.

Authors:  Masakatsu Tsurusaki; Keitaro Sofue; Hiromitsu Onishi; Satoshi Goshima; Atsushi Higaki; Hiroyoshi Isoda; Hiroki Haradome; Kazunari Ishii; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2020-10-06       Impact factor: 2.374

8.  Gadoxetate disodium-induced tachypnoea and the effect of dilution method: a proof-of-concept study in mice.

Authors:  Hiroyuki Akai; Koichiro Yasaka; Masanori Nojima; Akira Kunimatsu; Yusuke Inoue; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2017-09-11       Impact factor: 5.315

9.  Evaluation of incidence of acute transient dyspnea and related artifacts after administration of gadoxetate disodium: a prospective observational study.

Authors:  Luigi Grazioli; Riccardo Faletti; Barbara Frittoli; Giacomo Battisti; Roberta Ambrosini; Laura Romanini; Marco Gatti; Paolo Fonio
Journal:  Radiol Med       Date:  2018-08-06       Impact factor: 3.469

10.  CAIPIRINHA-Dixon-TWIST (CDT)-VIBE MR imaging of the liver at 3.0T with gadoxetate disodium: a solution for transient arterial-phase respiratory motion-related artifacts?

Authors:  Leonhard Gruber; Vera Rainer; Michaela Plaikner; Christian Kremser; Werner Jaschke; Benjamin Henninger
Journal:  Eur Radiol       Date:  2017-12-20       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.